216 related articles for article (PubMed ID: 8027221)
1. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
Fukumoto S; Matsumoto T; Takebe K; Onaya T; Eto S; Nawata H; Ogata E
J Clin Endocrinol Metab; 1994 Jul; 79(1):165-70. PubMed ID: 8027221
[TBL] [Abstract][Full Text] [Related]
2. Recovery of parathyroid hormone secretion during correction of tumor-associated hypercalcemia.
Body JJ; Dumon JC; Seraj F; Cleeren A
J Clin Endocrinol Metab; 1992 Jun; 74(6):1385-8. PubMed ID: 1592885
[TBL] [Abstract][Full Text] [Related]
3. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
[TBL] [Abstract][Full Text] [Related]
4. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
7. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
Blind E; Raue F; Meinel T; Wüster C; Ziegler R
Horm Metab Res; 1993 Jan; 25(1):40-4. PubMed ID: 8428711
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population.
Lee JK; Chuang MJ; Lu CC; Hao LJ; Yang CY; Han TM; Lam HC
J Endocrinol Invest; 1997; 20(7):404-9. PubMed ID: 9309539
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
Schilling T; Pecherstorfer M; Blind E; Leidig G; Ziegler R; Raue F
J Clin Endocrinol Metab; 1993 Mar; 76(3):801-3. PubMed ID: 8445039
[TBL] [Abstract][Full Text] [Related]
10. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.
Body JJ; Dumon JC; Thirion M; Cleeren A
J Bone Miner Res; 1993 Jun; 8(6):701-6. PubMed ID: 8328312
[TBL] [Abstract][Full Text] [Related]
11. Hypercalcemic complication in patients with oral squamous cell carcinoma.
Iwase M; Takemi T; Manabe M; Nagumo M
Int J Oral Maxillofac Surg; 2003 Apr; 32(2):174-80. PubMed ID: 12729778
[TBL] [Abstract][Full Text] [Related]
12. Malignancy hypercalcemia: evaluation of parathyroid function and response to treatment.
Mallette LE; Beck P; Vandepol C
Am J Med Sci; 1991 Oct; 302(4):205-10. PubMed ID: 1928231
[TBL] [Abstract][Full Text] [Related]
13. A dose-finding study of zoledronate in hypercalcemic cancer patients.
Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
[TBL] [Abstract][Full Text] [Related]
14. Plasma PTH and PTH-rP levels and clodronate therapy in cancer patients with hypercalcemia.
Su RJ; Chang CC; Tsai KS
J Formos Med Assoc; 1993 Nov; 92(11):977-82. PubMed ID: 7910069
[TBL] [Abstract][Full Text] [Related]
15. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
16. [The efficacy and safety of intravenous bisphosphonates in the treatment of primary hyperparathyroidism complicated by hypercalcemia crisis].
Han GY; Wang O; Xing XP; Meng XW; Lian XL; Guan H; Ye W; Xia WB; Li M; Jiang Y; Hu YY; Liu HC; Cui QC
Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):729-33. PubMed ID: 20079207
[TBL] [Abstract][Full Text] [Related]
17. Effects of YM175, a new-generation bisphosphonate, on hypercalcemia induced by tumor-derived bone resorbing factors in rats.
Takahashi K; Shirahata A; Fukushima S; Kokubo S; Teramura K; Usuda S
Jpn J Pharmacol; 1998 Feb; 76(2):155-63. PubMed ID: 9541278
[TBL] [Abstract][Full Text] [Related]
18. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
19. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
Grill V; Murray RM; Ho PW; Santamaria JD; Pitt P; Potts C; Jerums G; Martin TJ
J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
[TBL] [Abstract][Full Text] [Related]
20. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
